Die CDP World war dieses Jahr besonders aufregend, vor allem weil ein großes Thema der Veranstaltung die Maximierung des Potenzials von AI und GenAI in der CDP war.
Artificial intelligence is transforming the world of clinical trials, promising to cut drug development timelines in half.
In a context where technological innovation is redefining standards of performance and efficiency, BNP Paribas' "AI for Efficiency" program, developed in collaboration with Artefact, stands out as an ambitious model for transforming commercial banking through artificial intelligence. This project demonstrates how a structured, value-driven approach can not only optimize processes but also address the challenges of an ever-evolving industry.
Artefact mentioned in this interview from Brelotte Ba, deputy CEO of Orange Middle East and Africa, by Connecting Africa, on Orange's latest AI and GenAI projects.
Since its explosive emergence in mid-2022, generative AI has quickly captured global attention. What initially centered on the language modality has since expanded into exciting new avenues, including image, audio, and video models. Early in 2023, speculation about the technology's potential impact on businesses across various industries grew, accompanied by exciting early adoption cases. As more developers began building solutions with these models, the general perception shifted toward the continuous emergence of newer, larger, and hopefully better versions of the most widely used models.
Generative AI is a game-changer with applications across industries. Companies are actively discussing it, venture capitalists are heavily investing, and both employees and users are captivated, making it a focal point of attention. On one side, there are optimists who believe GenAI will be as revolutionary as the internet, while on the other, pessimists argue that it’s “just another fad” with no tangible value. Pragmatists are beginning to question whether the GenAI hype is fading. This piece aims to explore these perspectives.
Neuronale Metriken für die maschinelle Übersetzung (MT) zur Evaluierung sind aufgrund ihrer überlegenen Korrelation mit menschlichen Urteilen im Vergleich zu traditionellen lexikalischen Metriken immer prominenter geworden.
The discussion revolved around the transformative role of AI in clinical trials, supported by insights from Pfizer and Artefact, and highlighted in their collaborative white paper. It showcased concrete use cases, ecosystem mapping, and challenges to scaling AI innovations.
This roundtable explored the transformative role of GenAI in drug discovery, highlighting its potential to optimize processes, accelerate timelines, and foster collaboration in the pharmaceutical industry.
